Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Tailored treatment strategies for CLL

Danielle Brander • 2 Jun 2019
ASCO 2019
Chronic Lymphocytic Leukemia Leukemia Duvelisib Ibrutinib Idelalisib Venetoclax

Here, Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC, discusses tailored treatment strategies for chronic lymphocytic leukemia (CLL), including the use of B-cell receptor signalling inhibitors, and the BCL-2 inhibitor venetoclax. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Danielle Brander

The safety and efficacy of retreatment with venetoclax plus rituximab in R/R CLL 1:51
The safety and efficacy of retreatment with venetoclax plus rituximab in R/R CLL
Danielle Brander • 20 Jun 2024
Insights into the role of novel BTKis in the treatment landscape of R/R CLL 2:49
Insights into the role of novel BTKis in the treatment landscape of R/R CLL
Danielle Brander • 20 Jun 2024
Managing the potential cardiotoxicity associated with BTKis: important considerations 2:39
Managing the potential cardiotoxicity associated with BTKis: important considerations
Danielle Brander • 20 Jun 2024
The management of Richter’s transformation: current approaches and future outlooks 1:49
The management of Richter’s transformation: current approaches and future outlooks
Danielle Brander • 8 Dec 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals